BTK and mantle cell lymphoma: Given the aggressive biology of BTK inhibitor–refractory MCL and the encouraging efficacy of epcoritamab in other B‐cell malignancies, dedicated clinical trials are warranted to clarify its therapeutic potential and safety profile in this patient population.